-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 I3r1reXvmkUlPdoxyPk2KjTk2bIUC/2ujY48/N2bmeLQapaWxHvhXtvpchEJThuc
 iEdE9B7RBwsUbRinjR9QXw==

<SEC-DOCUMENT>0001102624-05-000260.txt : 20051020
<SEC-HEADER>0001102624-05-000260.hdr.sgml : 20051020
<ACCEPTANCE-DATETIME>20051020113844
ACCESSION NUMBER:		0001102624-05-000260
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20051020
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20051020
DATE AS OF CHANGE:		20051020

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12934
		FILM NUMBER:		051146640

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>immucellcorporation8k.htm
<DESCRIPTION>IMMUCELL CORPORATION 8-K
<TEXT>
<table cellpadding="3" border="0" cellspacing="0" width="100%">
<tr><td>
</td></tr>
</table>
<center>
<table border=0 cellpadding=3 cellspacing=0>
<tr><td align="center"><br><br>
<B>UNITED STATES</B><br>
<B>SECURITIES AND EXCHANGE COMMISSION</B><br>
Washington, D.C. 20549<p>
<hr size=1>
<p><b>FORM 8-K<p>
CURRENT REPORT
<p>
Pursuant to Section 13 or 15(d) of the<br>Securities Exchange Act of 1934.
</td>
</tr>
</table>
<p>
<b>
<table border=0 cellpadding=0 cellspacing=0>
<tr><td colspan=5 align=center>
<b>Date of Report: October   20, 2005</b><br>
(Date of earliest event reported)<br><br>
</td></tr>
<tr><td colspan=5 align=center>
<b>ImmuCell Corporation</b><br>
(Exact name of registrant as specified in its charter)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align=center colspan=2 valign="top">
<b>DE</b><br>
(State or other jurisdiction <br>of incorporation)
</td>
<td align=center width="20%" valign="top">
<b>0-15507</b><br>
(Commission File Number)
</td>
<td align=center colspan=2 valign="top">
<b>01-0382980</b><br>
(IRS Employer <br>Identification Number)
</td>
</tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align="center" colspan=2>
<b>56 Evergreen Drive, Portland, ME</b><br>
(Address of principal executive offices)
</td>
<td>&nbsp;</td>
<td align="center" colspan=2>
<b>04103</b><br>
(Zip Code)
</td>
</tr>
<tr><td colspan=5 align=center><br>
<b>(207) 878-2770</b><br>(Registrant's telephone number, including area code)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr><td colspan=5 align=center>
<b>Not Applicable</b><br>(Former Name or Former Address, if changed since last report)<br>
</td></tr>
</table>
</center>
<br><br>
</b>
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:<br>
<dl>
 <dd><font face="wingdings">o</font> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
 <dd><font face="wingdings">o</font> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  <br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  <br>
</dl>
<hr size=1>
<table width=100%>
<tr><td width="100%">
<b>Item 2.02. Results of Operations and Financial Condition</b></b><br>
<br>
On October 20, 2005 ImmuCell Corporation (the "Company") issued a press release announcing earnings results for the three and nine month periods ended September 30, 2005.  The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
<br>
<br>The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 of the Exchange Act, except as expressly set forth by specific reference in such filing.
<p>
<b>Item 9.01. Financial Statements and Exhibits</b></b><br>
<br><b>(a) Financial statements:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(b) Pro forma financial information:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(c) Exhibits</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  99.1 &nbsp; &nbsp; &nbsp; <a href="immucellcorporation.htm">Press Release of ImmuCell Corporation dated October   20, 2005</a></b>
<p>
<p>
<hr size=1>
<b><center>SIGNATURE</center></b>
<p>
&nbsp; &nbsp; &nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
              signed on its behalf by the undersigned hereunto duly authorized.<p>
</td></tr>
</table>
<br>
<table>
<tr>
<td width="50%" valign=top>
Dated: October   20, 2005<br>
</td>
<td>
<b>IMMUCELL CORPORATION</b>
<p>
By: <u>&nbsp;/s/ Michael F. Brigham &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </u> <br>
&nbsp; &nbsp; &nbsp;Michael F. Brigham<br>
&nbsp; &nbsp; &nbsp;<i>President and CEO</i><br>
</td></tr>
</table>
<hr>
<center>
<table border=0 width="100%">
<tr><td colspan=2>
<center><b>Exhibit Index</b></center>
</td>
</tr>
<tr>
<td width=50% align=center><b><u>Exhibit No.</u></b></td>
<td width=50% align=center><b><u>Description</u></b></td>
</tr>
<tr>
<td align=center>99.1</td>
<td align=center>Press Release of ImmuCell Corporation dated October   20, 2005</td>
</tr>
</table>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>immucellcorporation.htm
<DESCRIPTION>IMMUCELL CORPORATION PRESS RELEASE
<TEXT>

<p></p>
<b>ImmuCell Announces Financial Results for Third Quarter and First Nine Months of 2005</b>
<p>PORTLAND, ME -- 10/20/2005 --  ImmuCell Corporation (NASDAQ: ICCC) today
announced the results of its operations for the three and nine month
periods ended September 30, 2005.
</p>
<p>
The Company recognized net income of $109,000, or $0.04 per diluted share,
for the three months ended September 30, 2005, in contrast to a net loss of
$(5,000) during the same period in 2004.  For the nine months ended
September 30, 2005, the Company recognized net income of $448,000, or $0.15
per diluted share, in comparison to net income of $109,000, or $0.04 per
diluted share during the same period in 2004.
</p>
<p>
For the three months ended September 30, 2005, product sales decreased by
$25,000, or 3%, to $783,000, in comparison to the same period in 2004.  For
the six months ended September 30, 2005, product sales increased by
$181,000, or 12%, to $1,631,000, in comparison to the same period in 2004.
For the nine months ended September 30, 2005, product sales increased by
$392,000, or 15%, to $3,060,000, in comparison to the same period in 2004.
</p>
<p>
"We expect the sales of our lead product, First Defense&#174;, to be seasonal,
generally resulting in lower sales during the second and third quarters.
However, in contrast to net losses during the second and third quarters of
2003 and 2004, we have been profitable for both the second and third
quarters of 2005 due to increased gross margin and other revenues
associated with our December 2004 product development and marketing
agreement with Pfizer," commented Michael F. Brigham, president and CEO.
"Most of our R&amp;D efforts were invested in supporting the development of
Mast Out&#174; under our agreement with Pfizer."
</p>
<p>
The Company's cash, cash equivalents and short-term investments increased
by 10%, or $439,000, to $4,889,000 at September 30, 2005, as compared to
$4,450,000 at December 31, 2004.  Stockholders' equity increased by 7%, or
$564,000, to $8,293,000 at September 30, 2005, as compared to $7,729,000 at
December 31, 2004.  The Company had 2,847,000 shares of common stock
outstanding as of September 30, 2005.
</p>
<p>
<pre>
                                           (Unaudited)     (Unaudited)
                                      Three Months Ended  Nine Months Ended
                                      ------------------  -----------------
                                          September 30,      September 30,
                                         ---------------    ---------------
(In thousands, except per share amounts)  2005     2004      2005     2004
                                         ------   ------    ------   ------
Revenues:
Product sales                            $  783   $  808    $3,060   $2,668
Other revenues                              252       38       555       85
                                         ------   ------    ------   ------
Total revenues                            1,035      846     3,615    2,753

Cost and expenses:
Product costs                               267      343     1,178    1,103
Research and development expenses           358      272       925      735
Selling, general and administrative
 expenses                                   266      251       852      766
                                         ------   ------    ------   ------
Total costs and expenses                    891      866     2,955    2,604
                                         ------   ------    ------   ------

Net operating income (loss)                 144      (20)      660      149

Interest and other income                    41       15        94       41
                                         ------   ------    ------   ------

Income (loss) before income taxes           185       (5)      754      190
Income tax expense                           76        -       306       81
                                         ------   ------    ------   ------
Net income (loss)                        $  109   $   (5)   $  448   $  109
                                         ======   ======    ======   ======

Net income (loss) per common share:
Basic                                    $ 0.04   $(0.00)   $ 0.16   $ 0.04
Diluted                                  $ 0.04   $(0.00)   $ 0.15   $ 0.04

Weighted average common shares
 outstanding:
Basic                                     2,847    2,758     2,815    2,753
Diluted                                   3,024    2,758     2,993    2,957


                                   (Unaudited)
                              At September 30, 2005    At December 31, 2004
                              ---------------------    --------------------
(In thousands)
Cash, cash equivalents and
 short-term investments                      $4,889                  $4,450
Total assets                                  9,748                   9,530
Net working capital                           5,643                   4,998
Stockholders' equity                         $8,293                  $7,729
</pre>
</p>
<p>
ImmuCell Corporation is a biotechnology company that is developing,
manufacturing and selling products that improve animal health and
productivity in the dairy and beef industries.  Press releases and other
information about the Company are available at http://www.immucell.com.

</p>
<pre>
Contact:
Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106


</pre>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
